Watson’s Morning-After Pill Wins U.S. FDA Approval
This article is for subscribers only.
Watson Pharmaceuticals Inc. and HRA Pharma won U.S. approval for an emergency contraceptive that women can take up to five days after sex and will compete with Teva Pharmaceutical Industries Ltd.’s Plan B morning-after pill.
Watson will start selling the pill, to be called Ella, in the final three months of this year, the Corona, California-based company said today in a statement. The drug will be dispensed as a single dose and requires a prescription. Teva’s Plan B, which works for as much as 72 hours after unprotected sex, is available without a prescription for women ages 17 and older.